
SYRE Stock Forecast & Price Target
SYRE Analyst Ratings
Bulls say
Spyre Therapeutics is in a strong financial position with net assets of $251 million and a strong cash position of $225 million, giving them the necessary resources to continue their research and development efforts. Overall, Spyre Therapeutics presents a promising outlook for investors with their innovative approach to IBD and other inflammatory conditions, potential for growth in multiple indications, and strong financial standing.
Bears say
Spyre Therapeutics is facing potential challenges in developing commercially viable combination regimens due to the complexities of co-formulation and potential limitations with dosing frequencies. Additionally, updates from competitors in the space could impact shares positively or negatively, and the company may need to raise additional funds to support pipeline advancement, which could have a financial impact.
This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SYRE Analyst Forecast & Price Prediction
Start investing in SYRE
Order type
Buy in
Order amount
Est. shares
0 shares